It has shown efficacy in T-ALL and MCL in vitro and in vivo models, and in leukaemia PDX models harbouring two of the common Notch 1 activating mutations, i.e., mutations in the HD and PEST domains [304,305]. The gene discussed is NOTCH1; the disease is mantle cell lymphoma.